Propanc Biopharma Plans $5 Million IPO for Week of April 7th (PPCB)

Propanc Biopharma (PPCB) plans to raise $5 million in an IPO on the week of April 7th, IPO Scoop reports. The company will be issuing 1,000,000 shares at $4.00-$6.00 per share.

The company has a market-cap of $65.6 million.

D. Boral Capital (ex-EF Hutton) and Craft Capital served as the underwriters for the IPO.

Propanc Biopharma provided the following description of their company for its IPO: “(Incorporated in Delaware) We are a development-stage healthcare company that is currently focused on developing new cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancer. Utilizing our scientific and oncology consultants, we have developed a rational, composite formulation of anti-cancer compounds, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Our lead product candidate, PRP, is a variation upon our novel formulation and involves pro-enzymes, the inactive precursors of enzymes. Note: Net loss and revenue figures are for the fiscal year that ended June 30, 2024.  (Note: Propanc Biopharma is offering 1.0 million shares at a price range of $4.00 to $6.00 to raise $5.0 million, if priced at the $5.00 mid-point of its range, according to its S-1/A filing dated March 28, 2025.) “.

Propanc Biopharma was founded in 2007 and has 2 employees. The company is located at 302, 6 Butler Street Camberwell, VIC 3124 Australia and can be reached via phone at +61 03 9882 0780 or on the web at https://www.propanc.com/.